US 2024/0158774 A1Published application

Compositions and Methods for Treating Celiac Sprue Disease

AssigneeUniversity of Washington through its Center for Commercialization

InventorsJustin Bloomfield SIEGEL, David BAKER, Ingrid Swanson PULTZ

Life of this patent

Estimating the term…

Abstract

The invention provides compositions and methods for treating celiac sprue.

Claims18

Dependent claims

-29. (canceled)

An isolated polypeptide selected from the following group, or analogs thereof:

(a) an isolated polypeptide comprising an amino acid sequence, wherein the amino acid sequence comprises one, two, three, four, five, six, seven, eight, nine, ten, or eleven of the following substitutions from SEQ ID NO:
97:
(i) V or D at AA residue 116;
(ii) S, K, or G at AA residue 255;
(iii) D at AA residue 284;
(iv) T at AA residue 285;
(v) A, T, or N at AA residue 286;
(vi) S at AA residue 312;
(vii) N at AA residue 347;
(viii) T or A at AA residue 350;
(ix) N or G at AA residue 351;
(x) D at AA residue 354;
and (xi) S or H at AA residue 361;
(b) an isolated polypeptide comprising an amino acid sequence, wherein the amino acid sequence comprises one, two, three, four, five, six, seven, eight, nine, ten, or eleven of the following substitutions from SEQ ID NO:
98:
(i) D at AA residue 106;
(ii) S, K, or G at AA residue 246;
(iii) D at AA residue 275;
(iv) S at AA residue 276;
(v) A, T, or N at AA residue 277;
(vi) S at AA residue;
(vii) S at AA residue 338;
(viii) T or A at AA residue 341;
(ix) N or G at AA residue 342;
(x) Q or D at AA residue 345;
and (xi) S or H at AA residue 352;
(c) an isolated polypeptide comprising an amino acid sequence, wherein the amino acid sequence comprises one, two, three, four, five, six, seven, eight, nine, ten, or eleven of the following substitutions from SEQ ID NO:
99:
(i) D at AA residue 120;
(ii) S, K, or G at AA residue 259;
(iii) D at AA residue 288;
(iv) T at AA residue 289;
(v) A, T, N at AA residue 290;
(vi) A at AA residue 316;
(vii) S or N at AA residue 351;
(viii) A at AA residue 354;
(ix) N or G at AA residue 355;
(x) D at AA residue 358;
and (xi) S or H at AA residue 365;
(d) an isolated polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:
78;
(e) an isolated polypeptide comprising an amino acid sequence, wherein the amino acid sequence comprises one, two, three, four, five, six, seven, eight, nine, ten, or eleven of the following substitutions from SEQ ID NO:
102:
(i) V or D at AA residue 107;
(ii) S, K, or G at AA residue 245;
(iii) AA residue 274 is D;
(iv) AA residue 275 is T;
(v) AA residue 276 is A, T, or N;
(vi) AA residue 302 is S;
(vii) AA residue 337 is S or N;
(viii) AA residue 340 is T or A;
(ix) AA residue 341 is N or G;
(x) AA residue 344 is Q or D;
and (xi) AA residue 351 is S or H;
(f) an isolated polypeptide comprising an amino acid sequence, wherein the amino acid sequence comprises one, two, three, four, five, six, seven, eight, nine, ten, or eleven of the following substitutions:
(i) V or D at AA residue 76;
(ii) S, K, or G at AA residue 206;
(iii) D at AA residue 235;
(iv) S at AA residue 236;
(v) A, T, N at AA residue 237;
(vi) S at AA residue 262;
(vii) S or N at AA residue 297;
(viii) T or A at AA residue 300;
(ix) N or G at AA residue 301;
(x) Q or D at AA residue 302;
and (xi) S or H at AA residue 309;
(g) an isolated polypeptide comprising an amino acid sequence, wherein the amino acid sequence comprises one, two, three, four, five, six, seven, eight, nine, ten, or eleven of the following substitutions from SEQ ID NO:
104:
(i) D at AA residue 105;
(ii) S or K at AA residue 244;
(iii) D at AA residue 272;
(iv) S at AA residue 273;
(v) A, T, or N at AA residue 274;
(vi) S at AA residue 299;
(vii) N at AA residue 334;
(viii) T or A at AA residue 337;
(ix) N or G at AA residue 338;
(x) Q or D at AA residue 341;
and (xi) S or H at AA residue 348;
(h) an isolated polypeptide comprising an amino acid sequence, wherein the amino acid sequence comprises one, two, three, four, five, six, seven, eight, nine, ten, or eleven substitutions from SEQ ID NO:
105:
(i) V or D at AA residue 106;
(ii) S, K, or G at AA residue 244;
(iii) D at AA residue 273;
(iv) T at AA residue 274;
(v) A, T, N at AA residue 275;
(vi) S at AA residue 301;
(vii) N at AA residue 336;
(viii) T or A at AA residue 339;
(ix) N or G at AA residue 340;
(x) D at AA residue 343;
and (xi) S or H at AA residue 350;
(i) an isolated polypeptide comprising an amino acid sequence, wherein the amino acid sequence comprises one, two, three, four, five, six, seven, eight, nine, ten, or eleven of the following substitutions from SEQ ID NO:
106:
(i) V or D at AA residue 107;
(ii) S, K, or G at AA residue 245;
(iii) AA residue 274 is D;
(iv) AA residue 275 is T;
(v) AA residue 276 is A, T, or N;
(vi) AA residue 302 is S;
(vii) AA residue 337 is N;
(viii) AA residue 340 is T or A;
(ix) AA residue 341 is N or G;
(x) AA residue 344 is Q or D;
and (xi) AA residue 351 is S or H;
(j) an isolated polypeptide comprising an amino acid sequence, wherein the amino acid sequence comprises one, two, three, four, five, six, seven, eight, nine, ten, or eleven of the following substitutions from SEQ ID NO:
107:
(i) V or D at AA residue 104 is V or D;
(ii) S, K, or G at AA residue 241;
(iii) D at AA residue 270;
(iv) S at AA residue 271;
(v) D, A, T, or N at AA residue 272;
(vi) S at AA residue 398;
(vii) S at AA residue 33;
(viii) A at AA residue 336;
(ix) N or G at AA residue 337;
(x) D at AA residue 340;
and (xi) S or H at AA residue 347;
(k) an isolated polypeptide comprising an amino acid sequence, wherein the amino acid sequence comprises one, two, three, four, five, six, seven, eight, nine, ten, or eleven of the following substitutions from SEQ ID NO:
108:
(i) D at AA residue 104;
(ii) S, K, or G at AA residue 245;
(iii) D at AA residue 274;
(iv) S at AA residue 275;
(v) A, T, or N at AA residue 276;
(vi) S at AA residue 302;
(vii) S or N at AA residue 337;
(viii) T or A at AA residue 340;
(ix) N or G at AA residue 341;
(x) Q or D at AA residue 344;
and (xi) S or H at AA residue 351;
(l) an isolated polypeptide comprising an amino acid sequence, wherein the amino acid sequence comprises one, two, three, four, five, six, seven, eight, nine, ten, or eleven of the following substitutions from SEQ ID NO:
109:
(i) V or D at AA residue 118;
(ii) K or G at AA residue 250;
(iii) D at AA residue 279;
(iv) S at AA residue 280;
(v) A, T, or N at AA residue 281;
(vi) S at AA residue 307;
(vii) S or N at AA residue 342;
(viii) A at AA residue 345;
(ix) N or G at AA residue 346;
(x) Q or D at AA residue 349;
and (xi) S or H at AA residue 356;
(m) an isolated polypeptide comprising an amino acid sequence, wherein the amino acid sequence comprises one, two, three, four, five, six, seven, eight, nine, ten, or eleven of the following substitutions from SEQ ID NO:
110:
(i) V or D at AA residue 121;
(ii) S, K, or G at AA residue 253;
(iii) D at AA residue 282;
(iv) S at AA residue 283;
(v) A, T, or N at AA residue 284;
(vi) S at AA residue 310;
(vii) S at AA residue 345;
(viii) T or A at AA residue 348;
(ix) N or G at AA residue 349;
(x) Q or D at AA residue 352;
and (xi) S or H at AA residue 357;
(n) an isolated polypeptide comprising an amino acid sequence, wherein the amino acid sequence comprises one, two, three, four, five, six, seven, eight, nine, or ten of the following substitutions from SEQ ID NO:
111:
(i) S, K, or G at AA residue 111;
(ii) D at AA residue 139;
(iii) T or S at AA residue 140;
(iv) D, A, T or N at AA residue 141;
(v) S at AA residue 164;
(vi) S or N at AA residue 199;
(vii) T or A at AA residue 202;
(viii) N or G at AA residue 203;
(ix) Q or D at AA residue 204;
and (x) S or H at AA residue 211;
and
(o) an isolated polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:89.

168 more elements

Dependencies are inferred from the claim text.

Facts

Application: 18/357,617Filed 24 Jul 2023
Priority: 14 Aug 2013
Published: 16 May 2024
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

C12N 9/52
Proteinases , e.g. Endopeptidases: derived from bacteria or Archaea
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
A61P 29/00
Non-central analgesic, antipyretic or antiinflammatory agents
A61P 37/00
Drugs for immunological or allergic disorders

Family

Application61/865,787Us provisional application · filed 14 Aug 2013
Application14/911,630Continuation · filed 11 Feb 2016
Application16/360,190Continuation · filed 21 Mar 2019
Application16/693,057Continuation · filed 22 Nov 2019
Application17/230,230Continuation · filed 14 Apr 2021
Application18/357,617Continuation
US 10,266,815 B2Related patent
US 10,487,318 B1Related patent
US 11,008,558 B2Related patent
US 2016/0194621 A1Published application
US 2020/0123521 A1Published application
US 2021/0246437 A1Published application
US 2024/0158774 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results